Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Feature

Novel non-hydroxamic histone deactylase (HDAC) inhibitors in development from Miikana

Posted on: 14 Jul 05
Novel non-hydroxamic histone deactylase (HDAC) inhibitors in development from Miikana

Summary

The field of histone deacetylase inhibitors is moving into a new phase of development with candidates advancing nicely through clinical development. Milkana hasve recently developed a series of non-hydroxamic histone deactylase inhibitors which are likely to demonstrate an improved toxcity profile

The field of histone deacetylase inhibitors is moving into a new phase of development.  LeadDiscovery's report on Histone deacetylase inhibitors highlights the biology of the HDACs and the potential of their inhibitors. In profiling the various HDAC inhibitors in development we discuss the toxicological risk of hydroxamic acid, a moiety found in early inhibitors including SAHA. Our strategic evaluation discusses the development of HDAC inhibitors in which the hydroxamic acid has been replaced by other moieties. Here we highlight a series of mercaptoamides being developed by Miikana...[more]


Source LeadDiscovery


Featured on DailyUpdates-Oncology

LeadDiscovery

Last updated on: 27/08/2010 11:40:18

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.